The research focused on acute myocardial infarction, but EMMPRIN has an active role also in AS. Treatment resulted in improved heart contractility, reduced cardiac necrosis, and reduction of levels of MMP-2 and MMP-9 almost to those in healthy animals. The gene discussed is MMP9; the disease is myocardial infarction.